search
Back to results

Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging (INVADER MRI)

Primary Purpose

Peripheral Artery Disease, Vascular Disease, Critical Limb Ischemia

Status
Active
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Dexamethasone infusion
Drug coated balloon
Plain balloon angioplasty
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Peripheral Artery Disease focused on measuring angioplasty, peripheral artery disease, peripheral vascular disease, atherosclerosis, balloon angioplasty, dexamethasone, drug coated balloon, paclitaxel, walking, claudication

Eligibility Criteria

35 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Screening:

  1. Male or non-pregnant female ≥ 35 years of age
  2. Atherosclerotic, infrainguinal PAD
  3. Rutherford Clinical Category 2-6
  4. Stenosis detected by radiology that in the clinician's opinion is the reason for the PAD symptoms
  5. Patient is willing to provide informed consent and comply with the required follow up visits, testing schedule, and medication regimen
  6. Estimated Glomerular Filtration Rate (eGFR) ≥ 30 and/or threshold established by the local Institutional Review Board or Committee of Human Research

Procedural Criteria:

  1. De novo atherosclerotic lesion qualifying for angioplasty
  2. A patent artery proximal to the index lesion. Concomitant inflow procedures, including open femoral artery endarterectomy and/or stenting of the iliac arteries, are permissible.
  3. >50% diameter stenosis of the superficial femoral artery and/or popliteal artery (between the profunda and tibioperoneal trunk)
  4. Reference vessel diameter ≥3 mm and ≤ 8mm
  5. Successful wire crossing of lesion
  6. Successful angioplasty of the index lesion or part of the index lesion, defined as ≤30% residual lumen stenosis compared with adjacent non-diseased lumen diameter, without flow-limiting dissection

Exclusion Criteria:

Screening Criteria:

  1. Any contraindication to receiving an MRI
  2. Pregnant, nursing, or planning on becoming pregnant in < 2yrs
  3. Life expectancy of < 1 yr
  4. History of solid organ transplantation
  5. Patient actively participating in another investigational device or drug study
  6. History of hemorrhagic stroke within 3 months of index procedure
  7. Previous or planned surgical or interventional procedure within 30 days of index procedure
  8. Chronic renal insufficiency with eGFR < 30
  9. Prior bypass surgery, stenting, atherectomy or angioplasty of the index lesion
  10. Inability to take required study medications
  11. Contra-indication or known hypersensitivity to dexamethasone sodium phosphate, contrast media, gadolinium, aspirin or Plavix
  12. Systemic fungal infection
  13. Acute limb ischemia
  14. Prior participation of the index limb in the current study (contralateral treatment is allowed)
  15. Patient is being treated with long-term steroids (not including treatment of a bronchial condition with inhaled steroids)

Procedural Criteria:

  1. Index lesions extending into the tibial trifurcation or above the profunda. Note: the outflow tibial artery can be treated concomitantly. Similarly, the common femoral artery can be treated concomitantly, either with open endarterectomy and patch angioplasty or with endovascular methods. However, the index lesion cannot be contiguous with either the CFA or the tibial trifurcation.
  2. Circumferential calcification at index lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion catheter needle through the vessel wall
  3. Inadequate distal outflow defined as no patent tibial arteries (>50% stenosis). The outflow vessel can be established at the time of primary treatment
  4. Use of adjunctive therapies other than angioplasty. Chocolate balloons and/or scoring balloons are allowed, if used below reference diameter.

Sites / Locations

  • San Francisco VA Medical Center
  • University of Washington

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Dexamethasone

Drug Coated Balloon

Plain Balloon Angioplasty

Arm Description

Participants randomized to the Dexamethasone group will receive dexamethasone infusion to the adventitia of the artery following plain-old-balloon-angioplasty (POBA).

Participants randomized to the Drug Coated Balloon (DCB) group will not receive dexamethasone infusion to the adventitia of the artery following (POBA). They will receive additional angioplasty with a paclitaxel coated balloon.

Participants randomized to the Plain Balloon Angioplasty will receive balloon angioplasty (POBA) only. They will not receive adventital dexamethasone or paclitaxel.

Outcomes

Primary Outcome Measures

Change in Percent Wall Volume (PWV)
Percent Wall Volume (PWV) of the treated segment of artery will be measured by MRI.

Secondary Outcome Measures

Change in wall volume (WV) without a change in total vessel volume (TVV)
As measured by MRI
Change in perioperative inflammatory profile (MCP-1)
As measured by serum MCP-1
Change in perioperative inflammatory profile (CRP)
As measured by serum CRP
Change in perioperative inflammatory profile (IL-1beta)
As measured by serum IL-1beta
Change in ktrans
As measured by MRI
Change in lumen volume (LV) relative to total vessel volume (TVV)
As measured by MRI
Percentage of subjects with clinically significant restenosis that undergo reintervention of greater than or equal to 75% of the treated segment
As the subject undergoes reintervention, any treatment that overlaps with greater than or equal to 75% of the segment initially treated by the index procedure (treated segment) may result in obfuscation of the primary outcome measure .

Full Information

First Posted
April 1, 2016
Last Updated
November 2, 2021
Sponsor
University of California, San Francisco
Collaborators
University of Washington, National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT02807779
Brief Title
Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging
Acronym
INVADER MRI
Official Title
Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 10, 2016 (Actual)
Primary Completion Date
October 31, 2020 (Actual)
Study Completion Date
October 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
University of Washington, National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a prospective, multicenter, randomized trial to determine the mechanisms of vascular healing. The study will evaluate subjects with peripheral artery disease (PAD) who require an endovascular intervention of the femoro-popliteal (SFA) artery to restore blood flow to the leg.
Detailed Description
Peripheral artery disease (PAD) affects at least 12 million Americans annually with more than half a million patients undergoing an endovascular or surgical revascularization procedure in order to treat the disease. Unfortunately, about two-thirds of patients still have blockages in the leg arteries, even after these procedures. Advances in Magnetic resonance imaging (MRI) offer promise for understanding the mechanism of failure through insights into vessel wall composition, remodeling, and inflammation. Restenosis has a known relationship to inflammation. Advances in micro-catheter technologies offer the ability to deliver anti-inflammatory medications such as Dexamethasone (DEX) directly to the adventitia and advances in drug delivery on balloon surfaces to deliver paclitaxel to the intima of the artery. This study aims to investigate if patient-specific parameters affect angioplasty outcomes, if DEX has a biological effect on the vessel wall, and if this effect is through the reduction of inflammation. In response to an FDA issued "Letter to Healthcare Providers" dated August 9, 2019 that reported the "relative risk for increased mortality at 5 years was 1.57 (95% confidence interval 1.16 - 2.13), which corresponds to a 57% relative increase in mortality in patients treated with paclitaxel-coated devices," participant enrollment in the paclitaxel drug coated balloon arm was stopped and a plain balloon angioplasty arm was added to the protocol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Artery Disease, Vascular Disease, Critical Limb Ischemia
Keywords
angioplasty, peripheral artery disease, peripheral vascular disease, atherosclerosis, balloon angioplasty, dexamethasone, drug coated balloon, paclitaxel, walking, claudication

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
33 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dexamethasone
Arm Type
Experimental
Arm Description
Participants randomized to the Dexamethasone group will receive dexamethasone infusion to the adventitia of the artery following plain-old-balloon-angioplasty (POBA).
Arm Title
Drug Coated Balloon
Arm Type
Active Comparator
Arm Description
Participants randomized to the Drug Coated Balloon (DCB) group will not receive dexamethasone infusion to the adventitia of the artery following (POBA). They will receive additional angioplasty with a paclitaxel coated balloon.
Arm Title
Plain Balloon Angioplasty
Arm Type
Active Comparator
Arm Description
Participants randomized to the Plain Balloon Angioplasty will receive balloon angioplasty (POBA) only. They will not receive adventital dexamethasone or paclitaxel.
Intervention Type
Drug
Intervention Name(s)
Dexamethasone infusion
Other Intervention Name(s)
microinfusion catheter
Intervention Description
Participants will receive dexamethasone infusion following plain balloon angioplasty
Intervention Type
Device
Intervention Name(s)
Drug coated balloon
Intervention Description
Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
Intervention Type
Device
Intervention Name(s)
Plain balloon angioplasty
Intervention Description
Participants will receive plain balloon angioplasty only
Primary Outcome Measure Information:
Title
Change in Percent Wall Volume (PWV)
Description
Percent Wall Volume (PWV) of the treated segment of artery will be measured by MRI.
Time Frame
From Post-Operative Day One to 12 Months
Secondary Outcome Measure Information:
Title
Change in wall volume (WV) without a change in total vessel volume (TVV)
Description
As measured by MRI
Time Frame
From Post-Operative Day One to 12 Months
Title
Change in perioperative inflammatory profile (MCP-1)
Description
As measured by serum MCP-1
Time Frame
From Post-Operative Day One to 12 Months
Title
Change in perioperative inflammatory profile (CRP)
Description
As measured by serum CRP
Time Frame
From Post-Operative Day One to 12 Months
Title
Change in perioperative inflammatory profile (IL-1beta)
Description
As measured by serum IL-1beta
Time Frame
From Post-Operative Day One to 12 Months
Title
Change in ktrans
Description
As measured by MRI
Time Frame
From 1 Month to 6 Months
Title
Change in lumen volume (LV) relative to total vessel volume (TVV)
Description
As measured by MRI
Time Frame
From Post-Operative Day One to 12 Months
Title
Percentage of subjects with clinically significant restenosis that undergo reintervention of greater than or equal to 75% of the treated segment
Description
As the subject undergoes reintervention, any treatment that overlaps with greater than or equal to 75% of the segment initially treated by the index procedure (treated segment) may result in obfuscation of the primary outcome measure .
Time Frame
From Post-Operative Day One to 12 Months
Other Pre-specified Outcome Measures:
Title
Extended Clinical Adverse Events Monitoring
Description
Participant monitoring for clinical adverse events
Time Frame
From Post-Operative Day One to 36 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Screening: Male or non-pregnant female ≥ 35 years of age Atherosclerotic, infrainguinal PAD Rutherford Clinical Category 2-6 Stenosis detected by radiology that in the clinician's opinion is the reason for the PAD symptoms Patient is willing to provide informed consent and comply with the required follow up visits, testing schedule, and medication regimen Estimated Glomerular Filtration Rate (eGFR) ≥ 30 and/or threshold established by the local Institutional Review Board or Committee of Human Research Procedural Criteria: De novo atherosclerotic lesion qualifying for angioplasty A patent artery proximal to the index lesion. Concomitant inflow procedures, including open femoral artery endarterectomy and/or stenting of the iliac arteries, are permissible. >50% diameter stenosis of the superficial femoral artery and/or popliteal artery (between the profunda and tibioperoneal trunk) Reference vessel diameter ≥3 mm and ≤ 8mm Successful wire crossing of lesion Successful angioplasty of the index lesion or part of the index lesion, defined as ≤30% residual lumen stenosis compared with adjacent non-diseased lumen diameter, without flow-limiting dissection Exclusion Criteria: Screening Criteria: Any contraindication to receiving an MRI Pregnant, nursing, or planning on becoming pregnant in < 2yrs Life expectancy of < 1 yr History of solid organ transplantation Patient actively participating in another investigational device or drug study History of hemorrhagic stroke within 3 months of index procedure Previous or planned surgical or interventional procedure within 30 days of index procedure Chronic renal insufficiency with eGFR < 30 Prior bypass surgery, stenting, atherectomy or angioplasty of the index lesion Inability to take required study medications Contra-indication or known hypersensitivity to dexamethasone sodium phosphate, contrast media, gadolinium, aspirin or Plavix Systemic fungal infection Acute limb ischemia Prior participation of the index limb in the current study (contralateral treatment is allowed) Patient is being treated with long-term steroids (not including treatment of a bronchial condition with inhaled steroids) Procedural Criteria: Index lesions extending into the tibial trifurcation or above the profunda. Note: the outflow tibial artery can be treated concomitantly. Similarly, the common femoral artery can be treated concomitantly, either with open endarterectomy and patch angioplasty or with endovascular methods. However, the index lesion cannot be contiguous with either the CFA or the tibial trifurcation. Circumferential calcification at index lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion catheter needle through the vessel wall Inadequate distal outflow defined as no patent tibial arteries (>50% stenosis). The outflow vessel can be established at the time of primary treatment Use of adjunctive therapies other than angioplasty. Chocolate balloons and/or scoring balloons are allowed, if used below reference diameter.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Warren Gasper, MD
Organizational Affiliation
San Francisco VA Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David Saloner, PhD
Organizational Affiliation
San Francisco VA Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
San Francisco VA Medical Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94121
Country
United States
Facility Name
University of Washington
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging

We'll reach out to this number within 24 hrs